Total
0
Shares
Avita Medical (ASX:AVH) - CEO, Mike Perry
CEO, Mike Perry
Source: Avita Medical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • AVITA Medical (AVH) raked in $7 million in revenue during the first quarter, representing a 39 per cent increase year-on-year
  • The healthcare stock released its quarterly results on Tuesday, revealing its gross profit margin increased from 82 per cent to 85 per cent
  • Operating expenses also decreased 18 per cent during July to September, from $14.9 million in Q1 FY21 to $12 million in Q1 FY22
  • AVH isn’t expecting an increase in revenue over Q2, forecasting another $7 million will be brought in over the December period
  • Company shares are down 8.43 per cent at $4.67 per share

AVITA Medical (AVH) raked in $7 million in revenue during the first quarter of FY22, representing a 39 per cent increase year-on-year.

The regenerative medicine company released its latest quarterly results on Tuesday, revealing its gross profit margin increased from 82 per cent at the end of September last year to 85 per cent at the end of this quarter.

The healthcare stock’s operating expenses also decreased 18 per cent from July to September, from $14.9 million in Q1 FY21 to $12 million in Q1 FY22.

AVH is operating at a net loss, however, the business said it had reduced its loss from $10.2 million to $5.9 million over a one-year period.

AVITA CEO Mike Perry said it has been a busy quarter in terms of activities.

“I am pleased with the progress we made in the overall business this quarter, despite the hospital staffing shortages that impeded RECELL usage in burn procedures,” Dr Perry said.

AVITA’s RECELL system is used in the treatment of burns, and Dr Perry explained a trial using the technology continues.

“We saw continued acceleration of enrollment into our soft tissue reconstruction trial, which is now close to completion with 58 of 65 subjects,” he said.

“We look forward to expanding into this $450 million serviceable addressable market upon approval, beginning with our existing burn center accounts and leveraging our new TPT code in the outpatient setting.”

Looking ahead, AVH isn’t expecting additional revenue growth in the short term —forecasting $7 million in revenue over the second quarter of FY22.

Following the quarterly results release, AVITA Medical shares have dropped 8.43 per cent at $4.67 per share at 11:59 am AEDT.

AVH by the numbers
More From The Market Herald

" Petratherm (ASX:PTR) begins drilling at Comet

Pertatherm (PTR) has started prospect drilling at the Comet Gold Project in South Australia.

" Australian Dairy Nutritionals (ASX:AHF) and Wellnex Life (ASX:WNX) to launch organic A2 infant formula

Australian Dairy Nutritionals (AHF) and Wellnex Life (WNX) have established a joint venture to launch Australia’s first organic A2 protein infant formula.

" Cooper Metals (ASX:CPM) encouraged by rock chip assays at Mt Isa East

Cooper Metals (CPM) has released the last batch of results from rock chip geochemical sampling at the Mt Isa East project in Queensland.
Cirrus Networks (ASX:CNW) - CEO & Managing Director, Chris McLaughlin

" Cirrus Networks (ASX:CNW) signs partnership with global IT cloud security company

Cirrus (CNW) has signed a partnership with Gigamon to provide managed security services to governments and large enterprises.